182 related articles for article (PubMed ID: 34767871)
1. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.
van den Bosch CH; Jeremiasse B; van der Bruggen JT; Frakking FNJ; Loeffen YGT; van de Ven CP; van der Steeg AFW; Fiocco MF; van de Wetering MD; Wijnen MHWA
J Hosp Infect; 2022 May; 123():143-155. PubMed ID: 34767871
[TBL] [Abstract][Full Text] [Related]
2. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
[No Abstract] [Full Text] [Related]
3. Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials.
Liu Y; Zhang AQ; Cao L; Xia HT; Ma JJ
PLoS One; 2013; 8(11):e79417. PubMed ID: 24278133
[TBL] [Abstract][Full Text] [Related]
4. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211
[TBL] [Abstract][Full Text] [Related]
6. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis.
Sun Y; Wan G; Liang L
PLoS One; 2020; 15(4):e0231110. PubMed ID: 32255798
[TBL] [Abstract][Full Text] [Related]
7. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
Chu HP; Brind J; Tomar R; Hill S
J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973
[TBL] [Abstract][Full Text] [Related]
8. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study.
Savarese I; Yazami S; De Rose DU; Carkeek K; Campi F; Auriti C; Danhaive O; Piersigilli F
J Hosp Infect; 2024 Jan; 143():76-81. PubMed ID: 37972710
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic antibiotics for preventing Gram positive infections associated with long-term central venous catheters in oncology patients.
van de Wetering MD; van Woensel JB; Lawrie TA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD003295. PubMed ID: 24277633
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis.
Arechabala MC; Catoni MI; Claro JC; Rojas NP; Rubio ME; Calvo MA; Letelier LM
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010597. PubMed ID: 29611180
[TBL] [Abstract][Full Text] [Related]
11. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
Klek S; Szczepanek K; Hermanowicz A; Galas A
JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the efficacy of taurolidine in reducing catheter-related bloodstream infections for patients receiving parenteral nutrition.
Vernon-Roberts A; Lopez RN; Frampton CM; Day AS
JPEN J Parenter Enteral Nutr; 2022 Sep; 46(7):1535-1552. PubMed ID: 35233792
[TBL] [Abstract][Full Text] [Related]
13. Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates.
Chong CY; Ong RY; Seah VX; Tan NW; Chan MY; Soh SY; Ong C; Lim AS; Thoon KC
J Paediatr Child Health; 2020 Jan; 56(1):123-129. PubMed ID: 31145505
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of lock solutions for the prevention of catheter-related complications including infectious and bleeding events in adult haemodialysis patients: a systematic review and network meta-analysis.
Sheng KX; Zhang P; Li JW; Cheng J; He YC; Böhlke M; Chen JH
Clin Microbiol Infect; 2020 May; 26(5):545-552. PubMed ID: 31857208
[TBL] [Abstract][Full Text] [Related]
15. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of home parenteral nutrition patients using taurolidine as catheter lock: A long-term cohort study.
Wouters Y; Roosenboom B; Causevic E; Kievit W; Groenewoud H; Wanten GJA
Clin Nutr; 2019 Oct; 38(5):2210-2218. PubMed ID: 30292482
[TBL] [Abstract][Full Text] [Related]
17. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer.
Schoot RA; van Dalen EC; van Ommen CH; van de Wetering MD
Cochrane Database Syst Rev; 2013 Jun; (6):CD008975. PubMed ID: 23799867
[TBL] [Abstract][Full Text] [Related]
19. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients.
Neusser MA; Bobe I; Hammermeister A; Wittmann U
Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746
[TBL] [Abstract][Full Text] [Related]
20. Catheter lock solutions for reducing catheter-related bloodstream infections in paediatric patients: a network meta-analysis.
Guo Q; Lv Z; Wang H; Song L; Liu Y; Chen H; Zhou C
J Hosp Infect; 2021 Dec; 118():40-47. PubMed ID: 34560168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
